Tetraphase raises $15M for antibiotic work

Massachusetts-based Tetraphase Pharmaceuticals has closed the second tranche of its $25 million Series A financing. The $15 million tranche was funded by existing investors, including Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures. Tetraphase will use the funding to support the advancement of several antibiotic drug candidates.

"Since our inception, we have made significant progress, applying our unique technology to the development of several novel and potent antibiotic drug candidates," said Guy Macdonald, President and CEO. "We are very pleased that our investors share our enthusiasm for and confidence in our programs."

- take a look at TetraPhase's release

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.